As precision medicine reshapes neurology drug development, sponsors are seeking smarter ways to identify the right patients, integrate biomarkers and generate meaningful evidence across the development lifecycle. Neurology programs often face added complexity because disease progression, patient heterogeneity and endpoint selection can make study design and development decisions more difficult. This webinar explores how precision neurology strategies can help address these challenges by connecting patient identification approaches, biomarker strategies and real-world evidence across early development, clinical trials and post-launch planning. Attendees will learn how integrated evidence strategies can improve study efficiency, support more informed decision-making and help reduce development risk. The featured speakers will discuss how biomarkers, digital insights and real-world evidence can work together to deepen understanding of disease progression, refine trial design and support commercialization planning. The session will also examine how these approaches can help sponsors identify appropriate patient populations, evaluate meaningful outcomes and generate evidence that supports development and market access goals. Register for this webinar to learn how precision neurology can help accelerate neurology drug development through biomarkers, patient identification and real-world insight.